Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | AGER | Q15109 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15966073 | 0.88 | PARP1 (0.52) | PARP1KDM4EMAPTCYP1A2PLK1 | |
| SCHEMBL7218347 | 0.85 | PARP1 (0.50) | PARP1KDM4EMAPTCYP1A2PLK1 | |
| SCHEMBL2220449 | 0.84 | HDAC6 (0.47) | KDM4EMAPTCYP1A2TRPV1KMT2A | |
| SCHEMBL29289961 | 0.83 | PARP1 (0.49) | PARP1KDM4EMAPTCYP1A2PLK1 | |
| SCHEMBL2161057 | 0.82 | KMT2A (0.44) | PARP1KDM4EMAPTCYP1A2TRPV1 | |
| SCHEMBL27601273 | 0.82 | PARP1 (0.48) | PARP1KDM4EMAPTCYP1A2PLK1 | |
| SCHEMBL13118201 | 0.80 | KDM4E (0.49) | KDM4EMAPTCYP1A2TRPV1KMT2A | |
| SCHEMBL19539578 | 0.80 | ALDH1A1 (0.47) | PARP1KDM4EMAPTCYP1A2KMT2A | |
| SCHEMBL28677368 | 0.79 | L3MBTL1 (0.57) | PARP1KDM4EMAPTCYP1A2KMT2A | |
| SCHEMBL21590337 | 0.79 | PARP1 (0.46) | PARP1KDM4EMAPTCYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239452-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| US-8664248-B2 | Derivatives of pyridoxine for inhibiting HIV integrase | TAIMED BIOLOGICS, INC. (TW) | 2014-03-04 | — | — | US | disclosed |
| US-20120329827-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | AMBRILIA BIOPHARMA, INC. (CA) | 2012-12-27 | — | — | US | disclosed |
| US-8283366-B2 | Derivatives of pyridoxine for inhibiting HIV integrase | AMBRILIA BIOPHARMA, INC. (CA) | 2012-10-09 | — | — | US | disclosed |
| US-20110184028-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | TAIMED BIOLOGICS, INC. (TW) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184028-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | PNPO, IMPDH1, DPYD | PARP1 512/4885KDM4E 875/4885MAPT 2535/4885 |
| US-20200239452-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | PARP1 4215/4885KDM4E 1315/4885MAPT 609/4885 |
| US-20120329827-A1 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE | PNPO, IMPDH1, DPYD | PARP1 512/4885KDM4E 875/4885MAPT 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.